Gamma Knife Center, Department of Neurosurgery, Ajou University School of Medicine, 164 World Cup-ro, Yeongtong-Gu, Suwon, 16499, South Korea.
Yonsei University Graduate School, Seoul, South Korea.
J Neurooncol. 2018 May;137(3):559-565. doi: 10.1007/s11060-018-2745-4. Epub 2018 Jan 11.
We investigated the outcomes of gamma knife radiosurgery (GKRS) for elderly patients (≥ 65 years) with brain metastases, and identified survival-associated factors. We retrospectively analyzed data from 115 patients treated with GKRS for 1-15 brain metastases. The median patient age was 72 years; most primary tumors were pulmonary (n = 83). The mean lesion volume was 2.1 ± 4.8 mL. A mean dose of 19.3 Gy was delivered to the mean 63.9% isodose line. The median overall survival (OS) was 5.3 months (95% confidence interval [CI] 3.5-7.1). During follow-up (median, 5.1 months), 91 patients died of primary cancer progression while 1 died of unknown causes. The 6- and 12-month local control rates were 94.9 and 88.1%, respectively. On multivariate analysis, female sex (p = 0.005, hazard ratio [HR] 0.533, 95% CI 0.343-0.827) and a controlled primary tumor (p < 0.001, HR 0.328, 95% CI 0.180-0.596) were significantly favorable prognostic factors. Of non-small cell lung cancer patients with EGFR mutations, 76.5% were women (p = 0.005). The median OS of EGFR-mutant and EGFR-wildtype patients were 19.1 and 4.7 months, respectively (p = 0.080). Brain metastases < 3 mL showed better local control rates after GKRS (p = 0.005). GKRS produces favorable outcomes in women with brain metastases who are ≥ 65 years and have controlled primary tumors. Such patients are therefore suitable candidates for GKRS.
我们研究了伽玛刀放射外科(GKRS)治疗老年患者(≥65 岁)脑转移瘤的结果,并确定了与生存相关的因素。我们回顾性分析了 115 例接受 GKRS 治疗 1-15 个脑转移瘤的患者的数据。患者中位年龄为 72 岁;大多数原发肿瘤为肺部(n=83)。平均病变体积为 2.1±4.8mL。平均剂量为 19.3Gy,平均 63.9%等剂量线。中位总生存期(OS)为 5.3 个月(95%置信区间[CI]3.5-7.1)。在随访期间(中位时间为 5.1 个月),91 例患者因原发肿瘤进展而死亡,1 例患者死因不明。6 个月和 12 个月的局部控制率分别为 94.9%和 88.1%。多变量分析显示,女性(p=0.005,风险比[HR]0.533,95%CI 0.343-0.827)和控制良好的原发肿瘤(p<0.001,HR 0.328,95%CI 0.180-0.596)是显著的预后良好因素。非小细胞肺癌患者中,有 76.5%为女性(p=0.005)。EGFR 突变患者和 EGFR 野生型患者的中位 OS 分别为 19.1 个月和 4.7 个月(p=0.080)。GKRS 治疗后,脑转移瘤<3mL 的局部控制率更好(p=0.005)。GKRS 治疗老年(≥65 岁)和控制良好的原发性肿瘤脑转移女性患者效果良好。因此,这些患者是 GKRS 的合适候选者。